Vokietija - vokiečių - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

smithkline beecham pharma gmbh & co. kg - tetracyclinhydrochlorid, oleum-terebinthinae-landes-oxidationsprodukt - kapsel - tetracyclinhydrochlorid 250.mg; oleum-terebinthinae-landes-oxidationsprodukt 4.2mg

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ccd animal health pty ltd - oxytetracycline hydrochloride - oral powder, pre-mix - oxytetracycline hydrochloride antibiotic active 100.0 g/kg - parasiticides - calf | honey bees | pigs | poultry | sheep | beef calf | boar | bovine | breeders | broiler | calf - poddy | calf - preweaning | - bacterial calf scours | bacterial enteritis | chronic respiratory disease complex | colibacillosis | coryza | dermatitis | diptheria | european brood disease | infectious sinusitis | infectious synovitis | leptospirosis | mycoplasma hyopneumoniae | necrotic enteritis | oedema | pasteurella multocida | pasteurella spp. | pneumonia | salmonella | bacterial pneumonia | discharging sinuses | european foulbrood | fowl cholera | gangrenous | including b-lactamase producin | infectious coryza | l. hardjo | l. interrogans | l. pomona | l. tarassovi | ms | pasterellosis | pasteurellosis | physiological of the mammary g | post-weaning bacterial enterit | reduction of lung lesions | respiratory disease | salmonellosis | skin disorder | swine enzootic pneumonia

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

physicians total care, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth - unii:u015tt5i8h), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. pylera in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to resu

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

par pharmaceutical, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth cation - unii:zs9cd1i8ye), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori  has been shown to reduce the risk of duodenal ulcer recurrence. to reduce the development of drug-resistant bacteria and maintain the effectiveness of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules and other antibacterial drugs, bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

state of florida doh central pharmacy - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - tetracycline hydrochloride 500 mg - tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae and hemophilus influenzae . note: tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae , mycoplasma pneumoniae (eaton agent, and klebsiellasp .) - skin and soft tissue infections caused by streptococcus pyogenes , staphylococcus aureaus . (tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) - infections caused by rickettsia including rocky mountain spotted fever, typhus group infections, q fever, rickettsialpox. - psittacosis of ornithosis caused by chlamydia psittaci . - infections caused by chlamydia trachomatis such as uncomplicated urethral, endocer

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

avkare - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - tetracycline hydrochloride 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae and hemophilus influenzae . note: tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory tract infections caused by streptococcus

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - tetracycline hydrochloride 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes, streptococcus pneumoniae and hemophilus influenzae. note: tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory tract infections caused by strep

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

stat rx usa llc - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - tetracycline hydrochloride 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae and hemophilus influenzae . note: tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory tract infections caused by streptococcus pyog

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

actavis pharma, inc. - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - tetracycline hydrochloride 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride capsules and other antibacterial drugs, tetracycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae and haemophilus influenzae . note: tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory tract infections caused